Parexel International
NEWS
With new UK clinical trial rules landing in 2026, the EU Biotech Act on the horizon and China and Australia gaining ground, CROs are zeroing in on study timelines, AI/ML and data privacy as the industry’s next pressure points.
The CRO market in the APAC region is thriving, particularly in China, due to intense clinical trial and innovation development, with Western investors and pharma leaning in.
Addex Therapeutics announced it is canceling its Phase IIb/III study evaluating its drug dipraglurant due to patient recruiting, staffing and pandemic-related issues.
Upon completion of the merger, Parexel will be owned by EQT IX Fund and the private equity business within Goldman Sachs Asset Management.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s hires.
Datavant, the leader in helping healthcare organizations connect and share health data, announced a series of corporate updates.
Companies strengthen their leadership teams and boards of directors with these appointments.
Through the partnership, Parexel will integrate Datavant’s connectivity technology into the workflow of all of its clinical studies.
There has been a spate of recent news regarding the expansion of facilities and the expected job growth for the biopharma and life sciences industry. Here’s a look at some of those stories.
JOBS
IN THE PRESS